Phase 2Phase 3RegistrationApproved in 2017 Funapide (TV-45070, Nav1.7) Neuropathic pain Fasinumab ** Chronic Lower Back Pain Laquinimod Multiple sclerosis(primary progressive) Laquinimod Huntington disease Pridopidine Huntington disease Fremanezumab (anti CGRP) Chronic migraine (Global) Fremanezumab (anti CGRP) Episodic migraine(Global) Fremanezumab (anti CGRP) Cluster Headache(Global) Fasinumab ** Osteoarthritis pain(Global) Reslizumab* SC Asthma (Global) Austedo ® Tardive dyskinesia (U.S.) Azilect ® Parkinson’s disease(Japan)**** Reslizumab* IV Asthma (Growth Markets) CT-P10 *** Biosimilar(Rituxan® U.S.) CT-P6 *** Biosimilar(Herceptin® U.S.) BENDEKA® ***** CLL and NHL (Growth Markets) Vantrela ® ER Pain (U.S.) Austedo ® Huntington Disease (U.S.) ArmonAir ® RespiClick ® Asthma (U.S.) AirDuo ® RespiClick® Asthma (U.S.) QVAR® (beclomethasone diproprionate BAI) Asthma(U.S.)